Skip to main content

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B

  • 1st Edition, Volume 172 - October 11, 2023
  • Editors: Hari Shanker Sharma, Lars Wiklund, Aruna Sharma
  • Language: English
  • Hardback ISBN:
    9 7 8 - 0 - 4 4 3 - 2 9 4 6 8 - 6
  • eBook ISBN:
    9 7 8 - 0 - 4 4 3 - 2 9 4 6 9 - 3

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors, Part B, Volume 172 in the International Review of Neurobiol… Read more

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-morbidity Factors, Part B, Volume 172 in the International Review of Neurobiology series, includes chapters on Spinal cord injury induced exacerbation of Alzheimer's disease pathophysiology in the cord is reduced by topical application of nanowired cerebrolysin and antibodies to tumor necrosis factor alpha, Nanodelivery of histamine H3 receptor inverse agonist BF-2549 with clobenpropit a H3 receptor antagonist and H4 receptor agonist induced neuroprotection in spinal cord injury is potentiated by antioxidant compound H-290/51, and Neuromodulation and quality of life for patient with spasticity after spinal cord injury, and more.

Other sections cover Efficacy of invasive and non-invasive methods for the treatment of Parkinson´s disease: nanodelivery and enriched environment, Co-administration of DL-3-n-butylphthalide and neprilysin is neuroprotective in Alzheimer disease associated with brain injury, Nicotine Neurotoxicity Exacerbation following Engineered Ag and Cu (50-60 nm) nanoparticles intoxication, and Neuroprotection with nanowired delivery of antioxidant compound H-290/51 together with serotonin 5-HT3 receptor antagonist ondansetron.